Skip to content

BIOKEY: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

BIOKEY

BE 0719.913.808
NACE 72.101, Research and development on biotechnology
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
-€26,728
2024 · -€48,865+€22,137
Equity
-€203,275
2024 · -€176,547-€26,728
Cash
€616
2024 · €581+€34
Balance sheet total
€1,931
2024 · €5,582-€3,652

Largest movements

2024 to 2025
Assets
  • Receivables within one year -€3,686

    down €3,686 (-73.7%), from €5,001 to €1,315

Equity and liabilities
  • Other debts +€32,573

    up €32,573 (+33.8%), from €96,324 to €128,897

  • Profit (loss) carried forward -€26,728

    down €26,728 (-13.4%), from -€199,797 to -€226,525

  • Trade debts -€9,497

    down €9,497 (-100.0%), from €9,497 to €0

Income statement
  • Gross operating margin +€22,301

    up €22,301 (+46.2%), from -€48,288 to -€25,987

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 -€48,865
Gross operating margin +€22,301
Other operating charges -€166
Financial income -€0
Financial charges +€2
Result 2025 -€26,728

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations +€34
Investment €0
Financing €0
Cash 2024 €581
Net result for the year -€26,728
Receivables within one year +€3,686
Trade debts -€9,497
Other debts +€32,573
Cash 2025 €616
Every line side by side 27 lines
Line Code 2024 2025 Change %
Total assets 20/58 €5,582 €1,931 -€3,652 -65.4%
Current assets 29/58 €5,582 €1,931 -€3,652 -65.4%
Amounts receivable within one year 40/41 €5,001 €1,315 -€3,686 -73.7%
Other amounts receivable 41 €5,001 €1,315 -€3,686 -73.7%
Cash at bank and in hand 54/58 €581 €616 +€34 +5.9%
Total equity and liabilities 10/49 €5,582 €1,931 -€3,652 -65.4%
Equity 10/15 -€176,547 -€203,275 -€26,728 -15.1%
Contributions 10/11 €23,250 €23,250 = 0.0%
Profit (loss) carried forward 14 -€199,797 -€226,525 -€26,728 -13.4%
Amounts payable 17/49 €182,129 €205,205 +€23,076 +12.7%
Amounts payable after more than one year 17 €76,308 €76,308 = 0.0%
Other amounts payable 178/9 €76,308 €76,308 = 0.0%
Amounts payable within one year 42/48 €105,821 €128,897 +€23,076 +21.8%
Trade debts 44 €9,497 €0 -€9,497 -100.0%
Suppliers 440/4 €9,497 €0 -€9,497 -100.0%
Other amounts payable 47/48 €96,324 €128,897 +€32,573 +33.8%
Accrued charges and deferred income 492/3 €0 - =
Other operating charges 640/8 €531 €698 +€166 +31.3%
Gross operating margin 9900 -€48,288 -€25,987 +€22,301 +46.2%
Operating profit (loss) 9901 -€48,819 -€26,684 +€22,135 +45.3%
Financial income 75/76B €0 €0 -€0 -100.0%
Recurring financial income 75 €0 €0 -€0 -100.0%
Financial charges 65/66B €46 €44 -€2 -5.0%
Recurring financial charges 65 €46 €44 -€2 -5.0%
Profit (loss) for the period before taxes 9903 -€48,865 -€26,728 +€22,137 +45.3%
Profit (loss) for the period 9904 -€48,865 -€26,728 +€22,137 +45.3%
Profit (loss) for the period to be appropriated 9905 -€48,865 -€26,728 +€22,137 +45.3%

Source: filed annual accounts (NBB), fiscal years ended 30 April 2024 and 30 April 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 September 2026 via checked.be.